<DOC>
	<DOC>NCT01549119</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.</brief_summary>
	<brief_title>Phase I/IIa Dose-escalation Clinical Study of VAC-3S</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 infected patient Age between 18 and 55 years ART (AntiRetroviral Therapy) initiation 1 year ago Plasma HIV RNA below 50 copies per ml on three sequential occasions including V1 in the past 12 months CD4 T cell count above or equal to 200 cells per mm3, Nadir CD4 T cell count above or equal to 100 cells per mm3, Contraception in women with childbearing potential Any ART change within a month preceding screening. Chronic active liver disease, HIVHepatitis Coinfection. Immunotherapy in the past year, immunosuppressive treatment within the past month. History of autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>active immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>virulence</keyword>
	<keyword>innate immunity</keyword>
	<keyword>NK cells</keyword>
</DOC>